Related Experiment Videos
Analysis of the alpha4beta1 integrin-osteopontin interaction.
S T Barry1, S B Ludbrook, E Murrison
1Molecular Pharmacology, GlaxoWellcome Medicines Research Centre, Gunnels Wood Road, Stevenage, SG1 2NY, United Kingdom. stb38557@glaxowellcome.co.uk
Experimental Cell Research
|July 18, 2000
Summary
Researchers identified a novel binding site and peptide inhibitor for integrin alpha4beta1 on osteopontin. The SVVYGLR motif within osteopontin is key for alpha4beta1 interaction, offering potential therapeutic targets for inflammatory diseases.
Area of Science:
- Immunology
- Cell Biology
- Biochemistry
Background:
- Integrin alpha4beta1 mediates leukocyte extravasation during inflammation.
- It interacts with VCAM-1, fibronectin CS-1, and osteopontin (OPN).
Purpose of the Study:
- To map the alpha4beta1 binding region on human osteopontin (OPN).
- To identify specific motifs or peptides within OPN responsible for alpha4beta1 interaction.
Main Methods:
- GST fusion proteins were used to map the OPN binding site for alpha4beta1.
- Deletion mapping and peptide analysis were employed to define the interaction region.
- Mutational analysis of the RGD motif was performed.
Main Results:
- The alpha4beta1 binding region in OPN was localized to amino acid residues 125-168 (aa125-168).
- The RGD motif within this region did not affect alpha4beta1 binding.
- Peptides aa132-146 and aa153-168 supported alpha4beta1 adhesion, with SVVYGLR (aa162-168) identified as a novel inhibitor.
Conclusions:
- The SVVYGLR motif (aa162-168) is the primary binding site for integrin alpha4beta1 on OPN.
- SVVYGLR serves as a novel peptide inhibitor of alpha4beta1 binding to OPN and fibronectin CS-1.